Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4

Dore, 2014, Hepatitis C disease burden and strategies to manage the burden, J Viral Hepat, 21, 1, 10.1111/jvh.12253 Razavi, 2014, The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm, J Viral Hepat, 21, 34, 10.1111/jvh.12248 Waked, 2014, The current and future disease burden of chronic hepatitis C virus infection in Egypt, Arab J Gastroenterol, 15, 45, 10.1016/j.ajg.2014.04.003 Guerra, 2012, HCV burden of infection in Egypt: results from a nationwide survey, J Viral Hepat, 19, 560, 10.1111/j.1365-2893.2011.01576.x Gower, 2014, Global epidemiology and genotype distribution of the hepatitis C virus, J Hepatol, 61, S45, 10.1016/j.jhep.2014.07.027 Breban, 2013, Towards realistic estimates of HCV incidence in Egypt, J Viral Hepat, 20, 294, 10.1111/j.1365-2893.2012.01650.x Antaki, 2010, The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report, Liver Int, 30, 342, 10.1111/j.1478-3231.2009.02188.x 2012, Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection–Egypt, 2001–2012, MMWR Morb Mortal Wkly Rep, 61, 545 Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 Kowdley, 2013, Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial, Lancet, 381, 2100, 10.1016/S0140-6736(13)60247-0 Koff, 2014, Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection, Aliment Pharmacol Ther, 10.1111/apt.12601 Frank, 2000, The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt, Lancet, 355, 887, 10.1016/S0140-6736(99)06527-7 Ruane, 2015, Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, J Hepatol, 62, 1040, 10.1016/j.jhep.2014.10.044 Moreno, 2015, Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4, J Hepatol, 62, 1047, 10.1016/j.jhep.2014.12.031 Hézode, 2014, Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study, Gut Hézode, 2014, Daclatasvir in combination with peginterferon alfa-2a and ribavirin for treatment-naïve patients with HCV genotype 4 infection phase 3 COMMAND-4 results, Open Forum Infect Dis, 1, 10.1093/ofid/ofu052.527 Jensen, 2015, Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders, J Hepatol, 63, 30, 10.1016/j.jhep.2015.02.018 Hassanein, 2015, A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection, J Hepatol, 62, 1204, 10.1016/j.jhep.2014.12.025 Hézode, 2015, Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial, Lancet, 10.1016/S0140-6736(15)60159-3 Kapoor, 2014, All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY Trial, Hepatology, 60, 321A